Immunovant Inc (IMVT) - Total Assets
Based on the latest financial reports, Immunovant Inc (IMVT) holds total assets worth $1.05 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IMVT operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Immunovant Inc - Total Assets Trend (2018–2025)
This chart illustrates how Immunovant Inc's total assets have evolved over time, based on quarterly financial data. See Immunovant Inc net assets for net asset value and shareholders' equity analysis.
Immunovant Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Immunovant Inc's total assets of $1.05 Billion consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.0% |
| Accounts Receivable | $2.51 Million | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Immunovant Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Immunovant Inc (IMVT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunovant Inc's current assets represent 98.9% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 92.0% of total assets in 2025, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Immunovant Inc Competitors by Total Assets
Key competitors of Immunovant Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Immunovant Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.74 | 6.04 | 21.79 |
| Quick Ratio | 15.74 | 6.04 | 21.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $976.68 Million | $344.23 Million | $390.24 Million |
Immunovant Inc - Advanced Valuation Insights
This section examines the relationship between Immunovant Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.97 |
| Latest Market Cap to Assets Ratio | 7.62 |
| Asset Growth Rate (YoY) | 16.4% |
| Total Assets | $776.22 Million |
| Market Capitalization | $5.91 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Immunovant Inc's assets at a significant premium (7.62x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Immunovant Inc's assets grew by 16.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immunovant Inc (2018–2025)
The table below shows the annual total assets of Immunovant Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $776.22 Million | +16.43% |
| 2024-03-31 | $666.71 Million | +64.28% |
| 2023-03-31 | $405.84 Million | -21.28% |
| 2022-03-31 | $515.56 Million | +24.99% |
| 2021-03-31 | $412.49 Million | +277.09% |
| 2020-03-31 | $109.39 Million | +26909.14% |
| 2019-03-31 | $405.00K | +257.87% |
| 2018-03-31 | $113.17K | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more